Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
11 enrolled 9 charts
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Phase 2 Completed
80 enrolled 13 charts
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Phase 1/2 Completed
43 enrolled 19 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
Phase 1 Completed
8 enrolled
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
Phase 1 Terminated
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
Phase 2 Completed
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
Phase 3 Completed
50 enrolled
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 1 Completed
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
Phase 1 Unknown
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Phase 2/3 Completed
24 enrolled
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
Phase 1/2 Completed
58 enrolled
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
Phase 1 Completed
1 enrolled
Interleukin-2 in Treating Patients With Mycosis Fungoides
Phase 1 Completed
30 enrolled
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
Phase 2 Completed
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Phase 2 Terminated
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Phase 1/2 Completed
25 enrolled
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Phase 2 Completed
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Phase 1/2 Completed
20 enrolled
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma
Phase 2 Completed
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
Phase 1 Completed